Publicaciones en colaboración con investigadores/as de Fondazione IRCCS Istituto Nazionale dei Tumori (10)

2024

  1. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

    Nature Communications, Vol. 15, Núm. 1

2023

  1. Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 2, pp. 212-221

2021

  1. OX40 agonist BMS-986178 alone or in combination with nivolumab and/or ipilimumab in patients with advanced solid tumors

    Clinical Cancer Research, Vol. 27, Núm. 2, pp. 460-472

2019

  1. Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer

    International Journal of Cancer, Vol. 145, Núm. 7, pp. 1991-2001

2015

  1. Consensus nomenclature for CD8+ T cell phenotypes in cancer

    OncoImmunology, Vol. 4, Núm. 4

2014

  1. Classification of current anticancer immunotherapies

    Oncotarget, Vol. 5, Núm. 24, pp. 12472-12508

2011

  1. Defining the critical hurdles in cancer immunotherapy

    Journal of Translational Medicine

2010

  1. Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009

    Cancer Immunology, Immunotherapy

2006

  1. Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma

    Cancer Research, Vol. 66, Núm. 4, pp. 2442-2450

2000

  1. Feeding dendritic cells with tumor antigens: Self-service buffet or a la carte?

    Gene Therapy, Vol. 7, Núm. 14, pp. 1167-1170